Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma.
暂无分享，去创建一个
N. André | B. Geoerger | J. Whitlock | D. Hargrave | M. Kieran | S. Leary | M. Russo | E. Bouffet | J. Hansford | K. Dasgupta | I. Dunkel | A. Broniscer | L. Moreno | I. Aerts | N. Nebot | K. Cohen | P. Hingorani | T. Hummel | A. Bertozzi-Salamon | L. Tseng | Kohinoor Dasgupta